AgingResearch.NewsJoin free

Phase 2Completed

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Phase II Trial of APR-246 in Combination With Azacitidine as Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplant

Sponsor
Aprea Therapeutics (Industry)
Enrollment
33 enrolled
Conditions
Acute Myeloid Leukemia or Myelodysplastic Syndromes
Interventions
APR-246
Ages
adults, older adults
Registry
NCT03931291

Full record on ClinicalTrials.gov

From the registry

A multi-center, open label, Phase II clinical trial to assess the safety and efficacy of APR-246 in combination with azacitidine as maintenance therapy after allogeneic HSCT (hematopoietic stem cell transplant) for patients with TP53 mutant AML or MDS.

Primary outcomes

  • To Assess Relapse-free Survival (RFS) in Patients With TP53 Mutated AML or MDS After Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT).

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered